



UNITED STATES PATENT AND TRADEMARK OFFICE

SEP 14 2005

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Mailed: September 14, 2005

Paul E. White
Pillsbury, Madison & Sutro LLP
Intellectual Property Group
1600 Tysons Blvd
McLean VA 22102

In re: Patent Term Extension
Application for
U.S. Patent No. 4,855,290

NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. 4,855,290, which claims the human drug product EVOXAC® (Cevimeline HCl), and a method of use of said product, is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be 1,118 days.

A single request for reconsideration of this final determination as to the length of extension of the term of the patent may be made if filed within one month of the date of this notice. Extensions of time under 37 CFR § 1.136(a) are not applicable to this time period. In the absence of such request for reconsideration, the Director will issue a certificate of extension, under seal, for a period of 1,118 days.

The period of extension has been calculated using the Food and Drug Administration's determination of the length of the regulatory review period published in the Federal Register of November 18, 2002 (67 Fed. Reg. 69533). Under 35 U.S.C. § 156(c):

$$\begin{aligned}\text{Period of Extension} &= \frac{1}{2} \text{ (Testing Phase)} + \text{Approval Phase} \\ &= \frac{1}{2} (1,230 \text{ days} - 0) + 503 \text{ days} \\ &= 1,118 \text{ days (3.1 years)}\end{aligned}$$

Since the regulatory review period began April 16, 1995, after the patent issued (August 8, 1989), the entire regulatory review period has been considered in the above determination of the length of the extension period 35 U.S.C. § 156(c).

Neither the limitations of 35 U.S.C. § 156(g)(6) nor the 14 year limitation of 35 U.S.C. § 156(c)(3) operate to reduce the period of extension determined above.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:

U.S. Patent No.:	4,855,290
Granted:	August 8, 1989
Original Expiration Date ¹ :	August 8, 2006
Applicant:	Abraham Fisher, et al.
Owner of Record:	State of Israel, Represented by Prime Minister's

¹Subject to the provisions of 35 U.S.C. § 41(b).

Office, Israel, Institute for Biological Research

Title: Derivatives of Quinuclidine
Classification: 514/278
Product Trade Name: EVOXAC® (Cevimeline HCl)
Term Extended: 1,118 days
Expiration Date of Extension: August 30, 2009

Any correspondence with respect to this matter should be addressed as follows:

By mail: Commissioner for Patents
Mail Stop Patent Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

By FAX: (571) 272-7744
Attn: Office of Patent Legal Administration

Telephone inquiries related to this determination should be directed to the undersigned at
(571) 272-7744.

Karin Ferriter

Karin Ferriter
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
HFD - 13
5600 Fishers Lane
Rockville, MD 20857

RE: EVOXAC® (Cevimeline HCl)
FDA Docket No. : 01E-0405

Attention: Claudia Grillo